NEW APPROACHES TO BRAIN TUMOR THERAPY CNS CONSORTIUM

这项建议的主要长期目标是改善 成人原发性脑肿瘤的治疗结果。这将是 通过促进I期和II期临床评价， 有前景的新药物、生物学方法、给药途径， 治疗原发性中央恶性肿瘤的试验设计 神经系统通过不断努力的新方法， 脑肿瘤治疗（NABTT）CNS联盟。“这个财团是 专门设计的联合收割机， 13家优秀医疗机构的能力（布朗 大学、哥伦比亚大学、埃默里大学、亨利福特医院、 约翰霍普金斯大学，马萨诸塞州总医院，莫菲特癌症 中心，西北大学[芝加哥]，亚拉巴马大学， 德克萨斯大学圣安东尼奥分校，宾夕法尼亚大学， 维克森林大学和华盛顿大学）对小学的影响 脑瘤 参与机构有（1）数量众多 成人原发性脑肿瘤患者，（2）专家 多学科临床团队照顾这些患者，（3） 广泛的临床和实验室资源，（4）数量惊人的 持续的高质量，临床相关，同行评审和NIH资助 临床和实验室脑肿瘤研究项目，（5）全国 在肿瘤学、药理学、新药开发、 I期和II期临床试验，神经外科和神经病理学（6） 在生物统计学、数据管理和 多机构研究的协调，以及（7）特殊 在临床护理和研究方面享有卓越的声誉。 的 联盟通过明确和顺利的 功能结构，强调临床试验设计，方案 开发、质量控制、研究监查和数据管理， 分析. 本建议的次要长期目标是 利用这个联盟来分享人类脑肿瘤标本， 其他临床和实验室数据，以进行额外的研究 关于（1）原发性脑肿瘤的基础生物学，（2） 原发性脑肿瘤新疗法的神经药理学，和（3） 改善成年原发性脑损伤患者的护理和生活质量 肿瘤的 这一目标将通过利用 参与机构和NABTT相关生物学研究 中心，NABTT药理学中心，和NABTT工作和 科学委员会。

The primary long-term objective of this proposal is to improve the therapeutic outcome for adults with primary brain tumors. This will be accomplished by fostering Phase I and II clinical evaluations of promising new agents, biologic approaches, routes of administration, and trial design in the treatment of primary malignancies of the central nervous system through the continued efforts the New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium." This consortium is specifically designed to combine and focus the experience, resources, and capabilities of thirteen outstanding medical institutions (Brown University, Columbia University, Emory University, Henry Ford Hospital, Johns Hopkins University, Massachusetts General Hospital, Moffitt Cancer Center, Northwestern University [Chicago], the University of Alabama, the University of Texas at San Antonio, the University of Pennsylvania, Wake Forest University, and Washington University) to bear on primary brain tumors. The participating institutions have (1) a large number of adult patients with primary brain tumors, (2) expert multidisciplinary clinical teams caring for these patients, (3) extensive clinical and laboratory resources, (4) a striking number of ongoing high quality, clinically relevant, peer-reviewed and NIH funded clinical and laboratory brain tumor research projects, (5) nationally recognized expertise in oncology, pharmacology, new drug development, Phase I and II clinical trials, neurosurgery, and neuropathology, (6) extensive expertise in biostatistics, data management, and the coordination of multi-institutional studies, and (7) exceptional reputations for excellence in clinical care and research. The consortium adds to these strengths with a well-defined and smoothly functioning structure, an emphasis on clinical trial design, protocol development, quality control, study monitoring, and data management and analysis. The secondary long-term objective of this proposal is to utilize this consortium to share human brain tumor specimens as well as other clinical and laboratory data to conduct additional research pertaining to (1) the basic biology of primary brain tumors, (2) the neuro-pharmacology of new therapies for primary brain tumors, and (3) improving the care and quality of life of adults with primary brain tumors. This objective will be reached using the strengths of the participating institutions and the NABTT Correlative Biology Research Center, The NABTT Pharmacology Center, and The NABTT Working and Scientific Committees.